{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:39Z","timestamp":1790931339514,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Nuclear Technology R&D Program","award":["HNKFHBZ202319(36)"],"award-info":[{"award-number":["HNKFHBZ202319(36)"]}]},{"name":"Shanghai Collaborative Innovation Project","award":["HCXBCY-2024-001"],"award-info":[{"award-number":["HCXBCY-2024-001"]}]},{"name":"the Key Program of the National Natural Science Foundation of China","award":["U23A20465"],"award-info":[{"award-number":["U23A20465"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Shanghai Municipal Science and Technology Commission","award":["23DZ2291400"],"award-info":[{"award-number":["23DZ2291400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08089-6","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:27:59Z","timestamp":1784525279000},"page":"7169-7179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-tracer PSMA\/FDG PET\/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging"],"prefix":"10.1007","volume":"53","author":[{"given":"Linjie","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6111-6408","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"8089_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/mou.0000000000001312","volume":"35","author":"N Roessler","year":"2025","unstructured":"Roessler N, Miszczyk M, Strewinsky N, Rajwa P, Shariat SF. Treatment of biochemical recurrence after primary therapy with curative intent. Curr Opin Urol. 2025;35:517\u201321. https:\/\/doi.org\/10.1097\/mou.0000000000001312.","journal-title":"Curr Opin Urol"},{"key":"8089_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","volume":"28","author":"SJ Freedland","year":"2025","unstructured":"Freedland SJ, Gao W, Lax A, Yang H, Ramaswamy K, Russell D, et al. Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. Prostate Cancer Prostatic Dis. 2025;28:809\u201316. https:\/\/doi.org\/10.1038\/s41391-024-00894-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"8089_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2017.07.011","volume":"8","author":"JD Evans","year":"2018","unstructured":"Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostate cancer\u2013specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol. 2018;8:28\u201339. https:\/\/doi.org\/10.1016\/j.prro.2017.07.011.","journal-title":"Pract Radiat Oncol"},{"key":"8089_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, et al. Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol. 2025;26:695\u2013706. https:\/\/doi.org\/10.1016\/s1470-2045(25)00197-4.","journal-title":"Lancet Oncol"},{"key":"8089_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","volume":"27","author":"L Wang","year":"2025","unstructured":"Wang L, Wang L, Wang X, Wu D. The Evolving Role of PSMA-PET\/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact. Curr Oncol Rep. 2025;27:774\u201387. https:\/\/doi.org\/10.1007\/s11912-025-01682-2.","journal-title":"Curr Oncol Rep"},{"key":"8089_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s44178-024-00118-4","volume":"3","author":"B Dai","year":"2024","unstructured":"Dai B, Wang H, Shi B, Xing J, Zhu S, He Z, et al. CACA guidelines for holistic integrative management of prostate cancer. Holist Integr Oncol. 2024;3:47. https:\/\/doi.org\/10.1007\/s44178-024-00118-4.","journal-title":"Holist Integr Oncol"},{"key":"8089_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12890-023-02377-9","volume":"23","author":"Y Hu","year":"2023","unstructured":"Hu Y, Wang P, Dai W. Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET\/CT in lung cancer and lymph node metastasis. BMC Pulm Med. 2023;23:73. https:\/\/doi.org\/10.1186\/s12890-023-02377-9.","journal-title":"BMC Pulm Med"},{"key":"8089_CR8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","volume":"52","author":"K Pabst","year":"2024","unstructured":"Pabst K, Mei R, L\u00fcckerath K, Hadaschik B, Kesch C, Rawitzer J, et al. Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [Ga]Ga-\/[F]F-PSMA-11\/-1007, [Ga]Ga-FAPI-46 and 2-[F]FDG PET\/CT: a pilot study. Eur J Nucl Med Mol Imaging. 2024;52:342\u201353. https:\/\/doi.org\/10.1007\/s00259-024-06891-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8089_CR9","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8089_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8089_CR11","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.eanmj.2025.100006","volume":"1","author":"R Boellaard","year":"2025","unstructured":"Boellaard R, Herrmann K, Barrington SF, Cranston I, Mottaghy FM, Hoekstra CJ, et al. [18F]FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 3.0. Eur J Nucl Med Mol Imaging. 2025;1:100006. https:\/\/doi.org\/10.1016\/j.eanmj.2025.100006.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8089_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11934-025-01268-2","volume":"26","author":"R Islam","year":"2025","unstructured":"Islam R, Desai S, Moran M, Golombos DM. The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions. Curr Urol Rep. 2025;26:46. https:\/\/doi.org\/10.1007\/s11934-025-01268-2.","journal-title":"Curr Urol Rep"},{"key":"8089_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.semnuclmed.2021.12.008","volume":"52","author":"E Mena","year":"2022","unstructured":"Mena E, Lindenberg L, Choyke P. The Impact of PSMA PET\/CT Imaging in Prostate Cancer Radiation Treatment. Semin Nucl Med. 2022;52:255\u201362. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.12.008.","journal-title":"Semin Nucl Med"},{"key":"8089_CR14","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.3390\/cancers14174293","volume":"14","author":"A Siltari","year":"2022","unstructured":"Siltari A, Syv\u00e4l\u00e4 H, Lou YR, Gao Y, Murtola TJ. Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor\u2019s Immune Environment. Cancers (Basel). 2022;14:4293. https:\/\/doi.org\/10.3390\/cancers14174293.","journal-title":"Cancers (Basel)"},{"key":"8089_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/ijo.2023.5522","volume":"62","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang W, Kong P, Feng K, Liu C, Sun T, et al. New insights into lipid metabolism and prostate cancer (Review). Int J Oncol. 2023;62:74. https:\/\/doi.org\/10.3892\/ijo.2023.5522.","journal-title":"Int J Oncol"},{"key":"8089_CR16","doi-asserted-by":"publisher","first-page":"217441","DOI":"10.1016\/j.canlet.2025.217441","volume":"611","author":"MT Hindes","year":"2025","unstructured":"Hindes MT, McElligott AM, Best OG, Ward MP, Selemidis S, Miles MA, et al. Metabolic reprogramming, malignant transformation and metastasis: Lessons from chronic lymphocytic leukaemia and prostate cancer. Cancer Lett. 2025;611:217441. https:\/\/doi.org\/10.1016\/j.canlet.2025.217441.","journal-title":"Cancer Lett"},{"key":"8089_CR17","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.21037\/qims-22-1420","volume":"13","author":"Y Yao","year":"2023","unstructured":"Yao Y, Civelek AC, Li XF. The application of (18)F-FDG PET\/CT imaging for human hepatocellular carcinoma: a narrative review. Quant Imaging Med Surg. 2023;13:6268\u201379. https:\/\/doi.org\/10.21037\/qims-22-1420.","journal-title":"Quant Imaging Med Surg"},{"key":"8089_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1053\/j.semnuclmed.2025.11.019","volume":"56","author":"M Vorster","year":"2026","unstructured":"Vorster M, Sathekge M. 18F-FDG PET\/CT for prediction of response in breast cancer. Semin Nucl Med. 2026;56:86\u201396. https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.019.","journal-title":"Semin Nucl Med"},{"key":"8089_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s42003-025-09333-9","volume":"9","author":"C Chinopoulos","year":"2025","unstructured":"Chinopoulos C. Catabolic rewiring in cancer impacts dietary interventions. Commun Biol. 2025;9:65. https:\/\/doi.org\/10.1038\/s42003-025-09333-9.","journal-title":"Commun Biol"},{"key":"8089_CR20","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.csbj.2023.04.003","volume":"21","author":"Q Meng","year":"2023","unstructured":"Meng Q, Fang Z, Mao X, Tang R, Liang C, Hua J, et al. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Comput Struct Biotechnol J. 2023;21:2631\u20139. https:\/\/doi.org\/10.1016\/j.csbj.2023.04.003.","journal-title":"Comput Struct Biotechnol J"},{"key":"8089_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s40134-020-00367-x","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Behr S. Acute Findings on FDG PET\/CT: Key Imaging Features and How to Differentiate Them from Malignancy. Curr Radiol Rep. 2020;8:22. https:\/\/doi.org\/10.1007\/s40134-020-00367-x.","journal-title":"Curr Radiol Rep"},{"key":"8089_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4:699\u2013715. https:\/\/doi.org\/10.1038\/s43018-023-00539-6.","journal-title":"Nat Cancer"},{"key":"8089_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.61882\/smmr.202501.07.02","volume":"1","author":"A Pasha","year":"2025","unstructured":"Pasha A, Hajiebrahimi N, Motallebi N, Eydi M. A Narrative Review of Recent Advances in Prostate-Specific Membrane Antigen (PSMA)-Based Diagnostics and Theranostics. Stud Multidisciplinary Med Res. 2025;1:12\u201328. https:\/\/doi.org\/10.61882\/smmr.202501.07.02.","journal-title":"Stud Multidisciplinary Med Res"},{"key":"8089_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22:26\u201345. https:\/\/doi.org\/10.1038\/s41585-024-00900-z.","journal-title":"Nat Rev Urol"},{"key":"8089_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3348\/kjr.2024.0439","volume":"25","author":"SJ Na","year":"2024","unstructured":"Na SJ, Ha S, Kim I-H, Lee JY. Description of FDG and Prostate-Specific Membrane Antigen PET\/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer. Korean J Radiol. 2024;25:1022\u20138.","journal-title":"Korean J Radiol"},{"key":"8089_CR26","doi-asserted-by":"publisher","first-page":"1607227","DOI":"10.3389\/fmed.2025.1607227","volume":"12","author":"CM Iacovitti","year":"2025","unstructured":"Iacovitti CM, Cuzzocrea M, Rizzo A, Bauckneht M, Delgado Bolton RC, Paone G, et al. Diagnostic value of dual-tracer PET\/CT with [(18)F]FDG and PSMA ligands in prostate cancer: an updated systematic review. Front Med (Lausanne). 2025;12:1607227. https:\/\/doi.org\/10.3389\/fmed.2025.1607227.","journal-title":"Front Med (Lausanne)"},{"key":"8089_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/RLU.0000000000005587","volume":"50","author":"L Bian","year":"2025","unstructured":"Bian L, Li P, Wang X, Hu S, Lei J, Zuo Y, et al. Dual-Tracer 18F-FDG and 68Ga-PSMA PET\/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy. Clin Nucl Med. 2025;50:143\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000005587.","journal-title":"Clin Nucl Med"},{"key":"8089_CR28","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.Ccr-20-0587","volume":"26","author":"B Wang","year":"2020","unstructured":"Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A Prospective Trial of 68Ga-PSMA and 18F-FDG PET\/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clin Cancer Res. 2020;26:4551\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0587.","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08089-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08089-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08089-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:21Z","timestamp":1790929941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08089-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8089"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08089-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-center retrospective study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center (No. 1612167-18) and conducted in accordance with the Declaration of Helsinki. Owing to the retrospective design and use of de-identified data, the requirement for written informed consent was waived.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (the study does not include any individual person\u2019s identifiable data, images, or videos).","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}